DatScan With Prototype Collimator
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - 75 |
| Updated: | 5/4/2018 |
| Start Date: | June 2015 |
| End Date: | September 2017 |
Investigating the Use of Siemens Prototype UHRSZ Collimator for Imaging DatScan SPECT/CT Imaging
A collimator is an accessory to a SPECT/CT scanner. It can be compared to a camera lens or
filter that enhances or improves photos. The prototype collimators are able to magnify target
organs about four times compared to the current collimators. In this study we are validating
a new collimator design, which will allow for quantitative measurement of dopamine receptors
within the brain, not previously performed using a single photon gamma camera.
filter that enhances or improves photos. The prototype collimators are able to magnify target
organs about four times compared to the current collimators. In this study we are validating
a new collimator design, which will allow for quantitative measurement of dopamine receptors
within the brain, not previously performed using a single photon gamma camera.
Previously PET/CT has been used for this measurement but the L-DOPA is not FDA approved and
thus of limited availability. DatScan (I123 ioflupane) is an FDA approved and clinically
indicated biomarker, which has a high binding affinity for presynaptic dopamine transporters
(DAT) in the brains of mammals, in particular the striatal region of the brain. A feature of
Parkinson's disease is a marked reduction in dopaminergic neurons in the striatal region. By
introducing an agent that binds to the dopamine transporters a quantitative measure and
spatial distribution of the transporters can be obtained. The use of SPECT/CT (with the new
validated collimators) and the FDA approved DATScan biomarker would allow for readily
available diagnosis of Parkinson's disease
thus of limited availability. DatScan (I123 ioflupane) is an FDA approved and clinically
indicated biomarker, which has a high binding affinity for presynaptic dopamine transporters
(DAT) in the brains of mammals, in particular the striatal region of the brain. A feature of
Parkinson's disease is a marked reduction in dopaminergic neurons in the striatal region. By
introducing an agent that binds to the dopamine transporters a quantitative measure and
spatial distribution of the transporters can be obtained. The use of SPECT/CT (with the new
validated collimators) and the FDA approved DATScan biomarker would allow for readily
available diagnosis of Parkinson's disease
Inclusion Criteria:
- all patients referred
Exclusion Criteria:
- anyone who wishes to not participate and cannot lay on the table for an additional 30
minutes.
We found this trial at
1
site
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
Click here to add this to my saved trials
